Ovid Therapeutics Inc. (OVID) Form 8-K — Jul 8, 2026
Ovid Therapeutics Inc. announced the departure of Jeffrey Rona, its Chief Business and Financial Officer, effective July 6, 2026. The company stated the transition was mutually agreed upon and not due to any disagreements regarding accounting, financial reporting, or internal controls. The Board of Directors immediately appointed Charles Carter, the Senior Vice President of Finance and Financial Planning, to succeed Mr.
Key figures
- Carter RSUGrant
- 50000
- Carter Base Salary
- 460000
- Rona Severance Months
- 12
- Rona Consulting Period End
- 2027-12-31
- Carter Additional Bonus Opportunity
- 75000
Price after filing
1 day: -4.8%7 days: -8.8%30 days: -2.9%
Close on the filing date to close N calendar days later (from $2.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.